FIELD: pharmaceuticals.
SUBSTANCE: group of inventions relates to pharmaceutical chemistry and includes a compound by the formula I or stereoisomers, tautomers and pharmaceutically acceptable salts thereof, (R)-N-(3-fluoro-4-((3-((1-hydroxypropane-2-yl)amino)-1H-pyrazolo[3,4-b]pyridine-4-yl)oxy)phenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, a pharmaceutical composition and a method for treating cancer based thereon. In the formula I, X1 constitutes CH or N; R1 constitutes hydrogen or a C1-C6 alkyl; R2 and G are selected from the groups listed in the claim; R9 constitutes hydrogen or halogen.
EFFECT: compound by the formula I, exhibiting an inhibitory effect against TAM and MET kinases, used for treating TAM-associated c-Met-associated cancer in a patient.
17 cl, 9 tbl, 201 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL CONDENSED PYRIDINE DERIVATIVES USED AS C-MET TYROSINE KINASE INHIBITORS | 2013 |
|
RU2619130C2 |
| MDM2 PROTEIN DESTRUCTORS | 2017 |
|
RU2743432C2 |
| POINT MUTATIONS IN TRK INHIBITOR-RESISTANT MALIGNANT TUMORS AND RELATED METHODS | 2016 |
|
RU2744852C2 |
| QUINAZOLIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | 2020 |
|
RU2797606C1 |
| IDENTIFICATION OF LKB1 MUTATION AS PROGNOSTIC BIOMARKER OF SENSITIVITY TO TOR-KINASE INHIBITORS | 2011 |
|
RU2565034C2 |
| QUINOLINE CARBOXAMIDE AND QUINOLINE CARBONITRILE DERIVATIVES AS mGluR2 NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS AND USE THEREOF | 2012 |
|
RU2610262C2 |
| PROTEIN TYROSINE KINASE RECEPTOR INHIBITOR COMPOSITIONS | 2009 |
|
RU2586212C2 |
| PYRAZOLPYRIMIDINE COMPOUNDS JAK INHIBITORS AND METHODS | 2009 |
|
RU2539568C2 |
| COMBINED THERAPY WITH TETRACYCLIC QUINOLONE ANALOGUES FOR CANCER TREATMENT | 2016 |
|
RU2752506C2 |
| COMBINATION THERAPY WITH TETRACYCLIC QUINOLONE ANALOGUES FOR TREATMENT OF CANCER | 2016 |
|
RU2786570C2 |
